Quantum Biopharma reported revenue of -$0.04M and net income of -$2.38M for the quarter ended Jun 2026, down 146.9% year over year. This income statement covers 31 quarters of results from Dec 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||||||||
| Revenue | 0.00M | 0.00M | -0.07M | 0.44M | -0.27M | -0.19M | -0.17M | 1.42M | 0.17M | 0.10M | 0.16M | 0.13M | 0.07M | 0.09M | 0.10M | -0.02M | -0.01M | -0.04M | |||||||||||||
| Operating items | |||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | -0.11M | 0.85M | 0.94M | 1.41M | 1.87M | 2.69M | 2.31M | 1.61M | 0.03M | -0.03M | 0.16M | 0.90M | 0.74M | 4.28M | 1.65M | 0.55M | 0.50M | 0.07M | 0.63M | 0.39M | |||||||||||
| Share-based Compensation (IS)Stock Comp. | 0.25M | 0.34M | 0.08M | 0.36M | 0.59M | 0.51M | 3.21M | 0.40M | 0.13M | 0.10M | 0.06M | 0.11M | 0.07M | -0.08M | 0.29M | 0.85M | 1.00M | 0.81M | 0.89M | 0.01M | |||||||||||
| Selling, General & AdministrativeSG&A | 3.99M | 3.82M | 3.53M | 4.97M | 3.65M | 2.30M | 2.72M | 1.87M | 3.07M | 1.37M | 1.92M | 2.31M | 3.25M | 1.93M | 1.33M | 3.31M | 3.04M | 1.37M | 1.32M | 1.76M | |||||||||||
| Other Operating ExpensesOther Opex | 1.25M | 1.45M | 1.18M | 1.49M | 1.73M | 1.66M | 4.82M | 5.35M | 0.21M | 0.46M | 0.18M | 0.25M | 0.19M | 0.03M | 0.42M | 0.99M | 1.14M | 0.94M | 1.02M | 0.14M | |||||||||||
| Operating ExpensesOpex | 5.13M | 6.12M | 5.65M | 7.87M | 7.25M | 6.66M | 9.84M | 8.83M | 3.31M | 1.80M | 2.26M | 3.46M | 4.18M | 6.24M | 3.40M | 4.85M | 4.68M | 2.37M | 2.97M | 2.29M | |||||||||||
| Operating IncomeOp. Inc | -5.13M | -6.12M | 5.65M | -7.87M | -7.25M | -6.66M | -9.96M | -3.31M | -8.72M | -2.26M | -3.46M | -4.18M | -6.24M | -3.40M | -4.85M | -4.68M | -2.37M | -2.97M | -2.29M | ||||||||||||
| EBIT | -5.13M | -6.12M | 5.65M | -7.87M | -7.25M | -6.66M | -9.96M | -3.31M | -8.72M | -2.26M | -3.46M | -4.18M | -6.24M | -3.40M | -4.85M | -4.68M | -2.37M | -2.97M | -2.29M | ||||||||||||
| Non-operating items | |||||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.00M | 0.03M | 0.02M | 0.02M | 0.02M | 135.00 | 667.00 | -380.00 | 12.00 | 0.01M | 0.01M | 0.01M | 0.00M | 0.02M | 0.12M | 0.09M | -0.07M | 0.02M | 0.08M | ||||||||||||
| Goodwill impairment chargesGoodwill Impair. | 0.48M | 3.84M | |||||||||||||||||||||||||||||
| Non Operating Investment IncomeNon-Op. Investment Inc. | -0.14M | 0.72M | -0.01M | -0.15M | -1.03M | 1.24M | 0.05M | ||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.28M | -0.66M | -0.24M | -0.10M | -0.04M | 0.38M | 0.21M | -0.33M | 0.02M | -0.01M | -0.01M | -0.74M | -0.19M | 0.11M | -0.01M | 0.04M | 0.04M | -0.45M | |||||||||||||
| Non Operating IncomeNon Op. Inc. | 0.02M | 380.00 | -0.01M | ||||||||||||||||||||||||||||
| Net income details | |||||||||||||||||||||||||||||||
| EBT | -5.13M | -6.15M | 5.63M | -7.88M | -7.27M | -6.66M | -9.96M | -3.31M | -8.72M | -2.27M | -3.46M | -4.19M | -6.24M | -3.42M | -4.97M | -4.77M | -2.30M | -2.99M | -2.38M | ||||||||||||
| Profit After TaxPAT | -5.13M | -6.15M | 5.63M | -7.88M | -7.27M | -6.66M | -9.96M | -3.31M | -8.72M | -2.27M | -3.46M | -4.19M | -6.24M | -3.42M | -4.97M | -4.77M | -2.30M | -2.99M | -2.38M | ||||||||||||
| Investment IncomeInv. Income | -0.91M | 0.91M | |||||||||||||||||||||||||||||
| Income from Non-Controlling InterestsInc. Minority | -5.49M | -0.07M | -18.16M | -2.09M | -3.35M | -4.02M | -5.46M | -8.74M | -9.77M | -4.75M | -3.70M | -13.75M | -3.09M | ||||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -5.61M | -6.16M | 5.46M | -7.97M | -7.13M | -6.15M | -9.96M | -8.83M | -1.13M | -34.81M | -2.27M | -3.46M | -4.19M | -6.24M | -3.42M | -4.97M | -4.77M | -2.30M | -2.99M | -2.38M | |||||||||||
| Income from Discontinued OperationsIncome (Discontinued) | -0.18M | -0.18M | -0.44M | 3.54M | 0.18M | 0.44M | -3.54M | 3.10M | |||||||||||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -5.79M | -6.35M | 5.91M | -4.42M | -7.13M | -6.15M | -9.94M | -5.72M | -1.13M | 1.62M | -2.09M | -3.35M | -4.02M | -6.01M | -8.74M | -9.77M | -4.75M | -3.94M | -13.75M | -3.09M | |||||||||||
| Income towards Parent CompanyParent Net Inc | -5.79M | -6.35M | 5.91M | -4.42M | -7.13M | -6.15M | -9.96M | -5.72M | -1.06M | 1.62M | -2.09M | -3.35M | -3.83M | -2.09M | -8.74M | -9.77M | -4.75M | -3.94M | -13.75M | -3.09M | |||||||||||
| Net Income towards Common StockholdersNet Income | -5.79M | -6.35M | 5.91M | -4.42M | -7.13M | -6.15M | -9.96M | -5.49M | -1.06M | -1.39M | -1.90M | -3.11M | -3.83M | -5.36M | -8.58M | -9.25M | -5.32M | -3.03M | -13.56M | -3.25M | |||||||||||
| Additional items | |||||||||||||||||||||||||||||||
| EPS (Basic) | -0.48 | -0.18 | 0.17 | -0.13 | -0.20 | -0.16 | -0.26 | -0.14 | -0.03 | -0.04 | -0.05 | -0.08 | -0.10 | -4.71 | -7.54 | -8.14 | -4.68 | -0.92 | -4.13 | -0.99 | |||||||||||
| EPS (Diluted) | -0.48 | -0.18 | 0.17 | -0.13 | -0.20 | -0.16 | -0.26 | -0.14 | -0.03 | -0.04 | -0.05 | -0.08 | -0.10 | -4.71 | -7.54 | -8.14 | -4.68 | -0.92 | -4.13 | -0.99 | |||||||||||
| Shares Outstanding | 12.04M | 34.95M | 34.95M | 34.95M | 34.95M | 38.73M | 38.73M | 38.73M | 38.73M | 39.59M | 39.59M | 39.59M | 39.59M | 1.14M | 1.14M | 1.14M | 1.14M | 3.29M | 3.29M | 3.29M | |||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 12.04M | 34.95M | 34.95M | 34.95M | 34.95M | 38.73M | 38.73M | 38.73M | 38.73M | 39.59M | 39.59M | 39.59M | 39.59M | 1.14M | 1.14M | 1.14M | 1.14M | 3.29M | 3.29M | 3.29M | |||||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 34.95M | 38.73M | 39.59M | 1.14M | 3.89M | ||||||||||||||||||||||||||
| EBITDA | -4.13M | 352.51M | 6.75M | -6.73M | -6.11M | 350.44M | -8.83M | -3.17M | 319.70M | -2.14M | -3.32M | -4.06M | 244.20M | -3.27M | -4.71M | -4.53M | -2.24M | -2.84M | -2.17M | ||||||||||||
| Interest ExpensesInt Expense | 0.00M | 0.03M | 0.02M | 0.02M | 0.02M | 135.00 | 667.00 | -380.00 | 12.00 | 0.01M | 0.01M | 0.01M | 0.00M | 0.02M | 0.12M | 0.09M | -0.07M | 0.02M | 0.08M |
Pull Quantum Biopharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=QNTM&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "QNTM", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=QNTM&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();